KR900701840A - 인슐린 유사체 - Google Patents

인슐린 유사체

Info

Publication number
KR900701840A
KR900701840A KR1019900700042A KR900700042A KR900701840A KR 900701840 A KR900701840 A KR 900701840A KR 1019900700042 A KR1019900700042 A KR 1019900700042A KR 900700042 A KR900700042 A KR 900700042A KR 900701840 A KR900701840 A KR 900701840A
Authority
KR
South Korea
Prior art keywords
positions
amino acid
asn
gln
insulin
Prior art date
Application number
KR1019900700042A
Other languages
English (en)
Inventor
요르겐 베일가르트 브랑게 엔스
하벨운트 스벤트
Original Assignee
안네 제헤르
노브-노르디스크 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안네 제헤르, 노브-노르디스크 아크티에 셀스카브 filed Critical 안네 제헤르
Publication of KR900701840A publication Critical patent/KR900701840A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

인슐린 유사체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. Asn이 A18,A21 및 B3의 1 또는그 이상의 위치에 존재하지 않거나 및/ 또는 Gln이 A5,A15 및 B4의 1 또는 그 이상의 위치에 존재하지 않으며, 다한 A21위치의 아미노산 잔기가 Asn과 다를 때, A15,B4 또는 A5위치의 아미노산 잔기의 하나가 Gln과 다르거나 또는 A18 또는 B3위치의 아미노산 잔기의 하나가 Asn과 다르고, 그리고 다만 A5위치의 아미노산 잔기가 Gln과 다를 때 A15 또는 B4위치의 아미노산 잔기의 하나가 Gln과 다르거나 또는 A18,A21 또는 B3위치의 아미노산 잔기의 하나가 Asn과 다른 것을 특징으로 하는 인슐린 유사체.
  2. 제1항에 있어서, Asn이 A18,A21 및 B3의 1 또는 그 이상의 위치에 존재하지 않거나 및/ 또는 Gln이 A15및/ 또는 B4위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  3. 제1항에 있어서, Asn이 A18,A21 및 B3의 1 또는 그 이상의 위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  4. 제1항에 있어서, Asn이 B3및 A18위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  5. 제1항에 있어서, Asn이 B3및 A21위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  6. 제1항에 있어서, Asn이 B3위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  7. 제1항에 있어서, Asn이 B3및 A21위치에 존재하지 않고 Gln이 A15위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  8. 제1항에 있어서, A18,A21 또는 B3위치에서 1 또는 그 이상의 아미노산 잔기가Glu,Asp,His,Ser,Thr,Val,Leu,lle,Ala,Met,Trp,Tyr,Gly 또는 Gln이고 및/ 또는 A5,A15및 B4위치에서 1 또는 그 이상의 아미노산 잔기가 Glu,Asp.His,Ser,Thr,Val,Leu,Ile,Ala,Met,Trp,Tyr 또는 Gly인 것을 특징으로 하는 인슐린 유사체.
  9. 제1항에 있어서, B3위치의 아미노산 잔기가 Asp,Gln,Ser,Thr 또는 Glu인 것을 특징으로 하는 인슐린 유사체.
  10. 상기 항의 어느 한 항에 따른 인슐린 유사체 또는 그것의 약학적으로 허용되는 염을 함유하는 것을 특징으로 하는 인슐린 환성을 가지는 인슐린 제제.
  11. LysB29가 GlyA1에 펩티드 결합 또는 다음식(I)
    -Ra-R1- (I)
    의 펩티드 사슬에 의하여 연결된 인슐린 우사제의 전구제를 코드하는 DNA-서열을 구성된 복제가능한 발현 비히클로 형질전환된 이스트 균주를 적당한 배지에서 배양하고, 배양액으로 부터 전구체를 회수하여 다음식 (Ⅱ)
    Q-0R″ (Ⅱ)
    의 아미노 화합물과 반응시키고, 물 및 유기용매의 혼합물중에서 촉매로서 트립신 또는 트립신-유사효소를 사용하고 가수분해에 의해 카르복시 보호기를 제거하는 것을 특징으로 하는 제1항에 따른 인간 인슐린의 제조 방법.
    다만 상기 식 (I)에서 R은 n개의 아미노산 잔기를 가지는 펩티드 사슬이고 n은 O내지 33의 정수이고 R1은 Lys 또는 Arg이며, 상기 식 (Ⅱ)에서 Q는 B3O위치에 삽입되는 바람직하게는 Thr인 아미노산 잔기이고 R은 카르복시 보호기이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700042A 1988-05-11 1989-05-10 인슐린 유사체 KR900701840A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK257988A DK257988D0 (da) 1988-05-11 1988-05-11 Nye peptider
DK88,2579 1988-05-11
PCT/DK1989/000117 WO1989010937A1 (en) 1988-05-11 1989-05-10 Insulin analogues

Publications (1)

Publication Number Publication Date
KR900701840A true KR900701840A (ko) 1990-12-04

Family

ID=8113334

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700042A KR900701840A (ko) 1988-05-11 1989-05-10 인슐린 유사체

Country Status (10)

Country Link
EP (1) EP0419504B1 (ko)
KR (1) KR900701840A (ko)
AU (1) AU615760B2 (ko)
DE (1) DE68912777T2 (ko)
DK (1) DK257988D0 (ko)
HU (1) HUT55442A (ko)
IE (1) IE65504B1 (ko)
NZ (1) NZ229108A (ko)
WO (1) WO1989010937A1 (ko)
ZA (1) ZA893508B (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
ES2266187T3 (es) 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
PT1926749E (pt) 2005-09-14 2011-09-29 Sanofi Aventis Deutschland Clivagem de precursores de insulinas por uma variante de tripsina
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
SG177567A1 (en) 2009-07-06 2012-02-28 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
EP2451471A1 (de) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Langsamwirkende insulinzubereitungen
WO2011012718A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs comprising an insulin linker conjugate
BR112012001988A2 (pt) 2009-07-31 2017-05-09 Sanofi Aventis Deutschland composição de insulina de ação prolongada
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
RU2014127270A (ru) 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Аналог человеческого инсулина и его ацилированное производное
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 is glycosylated isoforms
WO2014096985A2 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
SG11201601477VA (en) 2013-09-30 2016-04-28 Wockhardt Ltd Pharmaceutical composition
ES2676065T3 (es) 2013-10-07 2018-07-16 Novo Nordisk A/S Nuevo derivado de un análogo de la insulina
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3260548A1 (en) 2016-06-21 2017-12-27 Enzypep B.V. Enzymatic coupling of (oligo)peptides to the b-chain of an insulin receptor ligand
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
AU2018230478A1 (en) 2017-03-09 2019-09-12 Diamedica Inc. Dosage forms of tissue kallikrein 1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (de) * 1975-08-13 1977-02-24 Hoechst Ag Insulin-analoga mit biologischer wirkung
NZ187300A (en) * 1977-05-27 1982-08-17 Univ California Dna transfer vector and micro-organism modified to contain a nucleotide sequence equivalent to the gene of a higher organism
US4343898A (en) * 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
IE62879B1 (en) * 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives

Also Published As

Publication number Publication date
HU893263D0 (en) 1991-03-28
IE891536L (en) 1989-11-11
EP0419504A1 (en) 1991-04-03
NZ229108A (en) 1992-05-26
WO1989010937A1 (en) 1989-11-16
DE68912777T2 (de) 1994-05-11
AU3692889A (en) 1989-11-29
DE68912777D1 (de) 1994-03-10
IE65504B1 (en) 1995-11-01
HUT55442A (en) 1991-05-28
DK257988D0 (da) 1988-05-11
ZA893508B (en) 1990-01-31
EP0419504B1 (en) 1994-01-26
AU615760B2 (en) 1991-10-10

Similar Documents

Publication Publication Date Title
KR900701840A (ko) 인슐린 유사체
KR910700262A (ko) 사람 인슐린 유사체
US4038222A (en) Untriakontapeptide with opiate activity
KR870002165A (ko) 인슈린유사체 및 그의 제조방법
KR930009591A (ko) 트리-아르기닌 인슐린
KR850008681A (ko) 합성펩티드의 제조방법
EP0525838A3 (en) Growth hormone releasing factor analogs
AU566180B2 (en) Human pancreatic grf
KR930701483A (ko) Grf (쥐이알에프) 유사체 xi
US4098778A (en) β-Endorphin analog
CA1187872A (en) Pharmacologically active peptides
CA1255850A (en) Peptides with disulfide bridges and method
CA2002924A1 (en) Anti-Thrombins
RU2001101164A (ru) Новые аналоги инсулина с повышенным связыванием цинка
Lemaire et al. Synthesis and biological activity of. beta.-endorphin and analogs. Additional evidence for multiple opiate receptors
US4283329A (en) Pharmacologically active peptides
Schwartz et al. Synthesis of des (tetrapeptide B1-4) and des (pentapeptide B1-5) human insulin. Two biologically active analogs
Yamashiro et al. β‐ENDORPHIN: SYNTHESIS AND ANALGESIC ACTIVITY OF SEVERAL ANALOGS MODIFIED IN POSITIONS 2 AND 5
EP0292257A3 (en) Peptides having anf activity
Yamamoto et al. Synthesis of porcine leumorphin and some of its biological activities
KR850700246A (ko) Crf 유사체
EP0008196B1 (en) Pentapeptides, processes for their preparation, intermediates used in such processes, use in pharmaceutical compositions and compositions containing them
KR900701839A (ko) Crf 유사체
US4128541A (en) Pentapeptide with morphine- like activity
LILI et al. Studies on peptides. CLXV. Combination of a new amide-precursor reagent and trimethylsilyl bromide deprotection for the 9-fluorenylmethyloxycarbonyl-based solid-phase synthesis of chicken antral peptide

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application